Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR   US68827R1086

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
17.87(c) 17.98(c) 17.29(c) 17.44(c) 17.69(c) Last
177 779 145 913 156 434 140 071 84 619 Volume
+1.59% +0.62% -3.84% +0.87% +1.43% Change
More quotes
Financials ($)
Sales 2015 91,7 M
EBIT 2015 10,3 M
Net income 2015 16,0 M
Debt 2015 -
Yield 2015 -
Sales 2016 115 M
EBIT 2016 22,5 M
Net income 2016 35,0 M
Debt 2016 -
Yield 2016 -
PER 2015 38,46
PER 2016 18,05
Capi. / Sales 2015 6,63x
Capi. / Sales 2016 5,30x
Capitalization 608 M
More Financials
Company
Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets.The company operates its business through two segments: Therapeutics and Biosurgery segment.The... 
More about the company
Surperformance© ratings of Osiris Therapeutics, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on OSIRIS THERAPEUTICS, INC.
03/23 OSIRIS THERAPEUTICS : to Present at the 3rd Annual Regen Med Investor Day
03/20 OSIRIS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
03/14 OSIRIS THERAPEUTICS : Reports Fourth Quarter and Full Year 2014 Financial Result..
03/11 OSIRIS THERAPEUTICS : Reports Fourth Quarter and Full Year 2014 Financial Result..
03/10 OSIRIS THERAPEUTICS : Posts Fourth Quarter and Full Year 2014 Financial Results
03/05 OSIRIS THERAPEUTICS : OSIR) is Trading Lower on Unusual Volume for March 05
03/05 OSIRIS THERAPEUTICS : posts 4Q profit
03/05 OSIRIS THERAPEUTICS : Reports Fourth Quarter and Full Year 2014 Financial Result..
More news
Sector news : Bio Therapeutic Drugs
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/05 Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q4 2014 Results - Earnin..
03/05 Osiris Therapeutics ups revenues 147% in FY14
03/05 Osiris Therapeutics (OSIR) Q4 2014 Results - Earnings Call Webcast
03/05 Osiris Therapeutics misses by $0.02, beats on revenue
03/04 Osiris Therapeutics reports tomorrow morning


Comments 
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF